Business Context and Reporting Period
Company: NanoViricides, Inc. (NNVC)
Filing Type: Form 8-K (Current Report)
Reporting Date: September 9, 2021 (Earliest event reported)
Business Context: The company operates in the biotechnology sector, focusing on treatments for coronavirus-derived human infections. This filing reports the entry into a material definitive licensing agreement and an executive employment extension.
Key Financial Metrics and Agreements
Revenue, Profit, and Cash Flow: The filing text does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the reporting period. This is a current report focused on specific events rather than periodic financial results.
Material Agreements and Obligations:
- Licensing Agreement (Item 1.01): Entered into an exclusive, worldwide license with TheraCour Pharma, Inc. for coronavirus treatments.
- Upfront Payment: None required.
- Milestone Payments (Potential):
- Milestone 1: 100,000 shares of Series A Convertible Preferred Stock.
- Milestone 2: 50,000 shares of Series A Convertible Preferred Stock.
- Milestone 3: $1,500,000 cash.
- Milestone 4: $2,000,000 cash.
- Milestone 5: $2,500,000 cash.
- Milestone 6: 100,000 shares of Series A Convertible Preferred Stock.
- Milestone 7: Licensor's option of either $5,000,000 cash or 500,000 shares of Series A Convertible Preferred Stock.
- Royalties: 15% of net sales of licensed products and income from sublicensed products.
- Development Fees: Costs (direct and indirect) plus 30%, payable in periodic installments.
- Deposit: Refundable deposit equal to estimated development costs for two months.
- Executive Compensation (Item 5.02):
- Dr. Anil R. Diwan (President) annual base salary: $400,000.
- Term Life Insurance: $2 million ($1 million assigned to Company).
- Equity Grant: 10,204 shares of Series A Preferred Shares (vesting quarterly from Sept 30, 2021 to June 30, 2022).
- Severance: 6 months' salary if terminated without cause.
Material Changes and Unusual Items
Licensing Structure: TheraCour retains the exclusive right to develop and manufacture the licensed products. NanoViricides has customary backup manufacture rights. The agreement includes a termination clause for material breach, with a 90-day cure period.
Security Characteristics: The Series A Convertible Preferred Stock issued under these agreements is non-transferrable, has no trading market, carries 9 votes per share, and is convertible into 3.5 common shares only upon a "change of control."
Interest Penalty: Payments to TheraCour not made within 90 days of the due date will incur interest at 1% per month.
Guidance, Outlook, and Risks
Outlook: The company is advancing its pipeline for coronavirus treatments through the TheraCour partnership. No specific financial guidance or revenue projections were provided in this filing.
Risks and Contingencies:
- Performance Risk: Significant cash and equity obligations are contingent upon achieving undefined milestones.
- Dependency: Reliance on TheraCour for exclusive development and manufacturing.
- Liquidity Risk: Future cash outflows for milestones ($6 million potential cash) and development fees could impact liquidity if milestones are achieved.
- Termination Risk: The license may be terminated by TheraCour for material breach.
Investor Verification Checklist
- Verify the specific definitions and timelines for Milestones 1 through 7 in the full License Agreement (Exhibit 10.1).
- Confirm the current cash position of the company to assess ability to fund potential milestone payments and development fees.
- Review the "change of control" definition to understand the convertibility triggers for the Series A Preferred Stock.
- Assess the financial health and manufacturing capacity of TheraCour Pharma, Inc., given their exclusive role in development and manufacturing.
- Check for any subsequent filings regarding the achievement of Milestone 1 or the payment of the initial development deposit.